Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call - Slideshow
Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET
Where Does Braveheart Bio (BRVE) Value Sit After AHA Data?
Braveheart Bio (BRVE), Why Is Attention Building Around It?
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio Q2 EPS $(2.51)
Braveheart Bio to Participate in Cantor Global Healthcare Conference
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
TD Cowen Initiates Coverage On Braveheart Bio with Buy Rating
Jefferies Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.